In our study, T2DM subjects were on medications to treat hyperglycemia (most commonly metformin, DPP-4 inhibitors, and basal insulin), hypertension (most commonly angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), and dyslipidemia (most commonly statins). The gene discussed is INS; the disease is metabolic syndrome.